Calithera Biosciences Company Profile (NASDAQ:CALA)

About Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences logoCalithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CALA
  • CUSIP: N/A
  • Web: www.calithera.com
Capitalization:
  • Market Cap: $564.07 million
  • Outstanding Shares: 35,476,000
Average Prices:
  • 50 Day Moving Avg: $16.29
  • 200 Day Moving Avg: $14.94
  • 52 Week Range: $2.20 - $20.05
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.14
  • P/E Growth: -0.27
Sales & Book Value:
  • Annual Revenue: $11.45 million
  • Price / Sales: 49.26
  • Book Value: $4.58 per share
  • Price / Book: 3.47
Profitability:
  • EBITDA: ($29,120,000.00)
  • Return on Equity: -26.72%
  • Return on Assets: -20.91%
Debt:
  • Current Ratio: 4.95%
  • Quick Ratio: 4.95%
Misc:
  • Average Volume: 491,192 shs.
  • Beta: 3.26
  • Short Ratio: 3.93
 

Frequently Asked Questions for Calithera Biosciences (NASDAQ:CALA)

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) announced its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.14. The business earned $7.26 million during the quarter, compared to analysts' expectations of $4.80 million. View Calithera Biosciences' Earnings History.

When will Calithera Biosciences make its next earnings announcement?

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Calithera Biosciences.

Where is Calithera Biosciences' stock going? Where will Calithera Biosciences' stock price be in 2017?

6 brokers have issued 12-month price targets for Calithera Biosciences' shares. Their predictions range from $5.00 to $20.00. On average, they anticipate Calithera Biosciences' stock price to reach $14.40 in the next twelve months. View Analyst Ratings for Calithera Biosciences.

What are analysts saying about Calithera Biosciences stock?

Here are some recent quotes from research analysts about Calithera Biosciences stock:

  • 1. According to Zacks Investment Research, "Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. " (7/13/2017)
  • 2. JMP Securities analysts commented, "Calithera Biosciences reports achievement of PK and PD goals in the Phase I trial of CB-1158, which entitles the company to receive a $12MM milestone payment as per its collaboration agreement with Incyte (INCY, MO, PT UR, Bayko); reiterate our Market Outperform rating and $12 price target based on a synthesis of our DCF, SOTP, and comparable company valuation methodologies. We view this early milestone achievement as further validation of the company's collaboration with INCY as well as of the subject of the agreement, CB-1158, a first-in-class arginase inhibitor and potential immunotherapeutic. CB-1158 has thus far demonstrated favorable pharmacologic activity in human subjects, with elevated plasma arginine levels consistent with those seen in preclinical cancer models. We remind investors that additional clinical data for CB-1158 in the setting of immuno-oncology are expected in mid-2017." (3/28/2017)

Who are some of Calithera Biosciences' key competitors?

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:

  • Susan M. Molineaux Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Curtis C. Hecht, Senior Vice President - Business and Corporate Development
  • Christopher J. Molineaux Ph.D., Senior Vice President - Development
  • Keith Orford M.D. Ph.D., Senior Vice President, Clinical Development
  • Eric B. Sjogren Ph.D., Senior Vice President - Drug Discovery
  • Stephanie Wong, Vice President - Finance, Secretary
  • Francesco Parlati Ph.D., Vice President - Research
  • Deepa R. Pakianathan Ph.D., Lead Independent Director
  • Sunil Agarwal M.D., Independent Director
  • Jonathan G. Drachman M.D., Independent Director

How do I buy Calithera Biosciences stock?

Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of Calithera Biosciences stock can currently be purchased for approximately $15.90.


MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Calithera Biosciences (NASDAQ:CALA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $14.40 (9.43% downside)
Consensus Price Target History for Calithera Biosciences (NASDAQ:CALA)
Price Target History for Calithera Biosciences (NASDAQ:CALA)
Analysts' Ratings History for Calithera Biosciences (NASDAQ:CALA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017William BlairInitiated CoverageOutperform -> OutperformN/AView Rating Details
6/12/2017HC WainwrightReiterated RatingBuy$14.00 -> $19.00LowView Rating Details
6/6/2017Wells Fargo & CompanyReiterated RatingOutperform$15.00 -> $20.00HighView Rating Details
4/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$16.00MediumView Rating Details
3/28/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $12.00MediumView Rating Details
1/24/2017Citigroup Inc.UpgradeSell -> Neutral$5.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$20.00 -> $12.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Calithera Biosciences (NASDAQ:CALA)
Earnings by Quarter for Calithera Biosciences (NASDAQ:CALA)
Earnings History by Quarter for Calithera Biosciences (NASDAQ CALA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.23)N/AView Earnings Details
8/8/2017Q2 2017($0.29)($0.15)$4.80 million$7.26 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.22)$1.40 million$4.19 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.48)($0.45)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.47)($0.44)ViewListenView Earnings Details
8/9/2016Q2($0.52)($0.55)ViewListenView Earnings Details
5/10/2016Q1($0.47)($0.52)ViewListenView Earnings Details
3/15/2016Q415($0.56)($0.44)ViewListenView Earnings Details
11/9/2015Q3($0.52)($0.49)ViewListenView Earnings Details
8/10/2015Q215($0.45)($0.44)ViewListenView Earnings Details
11/14/2014Q3 2014($0.28)($16.85)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Calithera Biosciences (NASDAQ:CALA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.17)($0.17)($0.17)
Q3 20172($0.27)($0.17)($0.22)
Q4 20172($0.30)($0.19)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Calithera Biosciences (NASDAQ:CALA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Calithera Biosciences (NASDAQ:CALA)
Insider Ownership Percentage: 16.30%
Institutional Ownership Percentage: 71.88%
Insider Trades by Quarter for Calithera Biosciences (NASDAQ:CALA)
Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)
Insider Trades by Quarter for Calithera Biosciences (NASDAQ:CALA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Adage Capital Partners Gp, L.LMajor ShareholderSell576,000$15.64$9,008,640.00View SEC Filing  
7/17/2017Keith OrfordVPSell2,120$18.31$38,817.20View SEC Filing  
7/6/2017Curtis HechtSVPSell700$18.00$12,600.00View SEC Filing  
5/19/2017Curtis HechtSVPSell650$16.00$10,400.00View SEC Filing  
3/22/2017Adage Capital Partners Gp, L.LMajor ShareholderBuy487,804$10.25$4,999,991.00View SEC Filing  
3/13/2017Curtis HechtSVPSell600$14.00$8,400.00View SEC Filing  
11/16/2016Adage Capital Partners Gp, L.LMajor ShareholderBuy500,000$3.15$1,575,000.00View SEC Filing  
11/16/2015Curtis HechtVPSell970$6.58$6,382.60View SEC Filing  
9/23/2015Adage Capital Partners Gp LlcMajor ShareholderBuy106,968$6.03$645,017.04View SEC Filing  
9/4/2015Adage Capital Partners Gp LlcMajor ShareholderBuy90,300$5.93$535,479.00View SEC Filing  
8/28/2015Adage Capital Partners Gp LlcMajor ShareholderBuy172,126$5.27$907,104.02View SEC Filing  
10/15/2014Adage Capital Partners Gp LlcMajor ShareholderBuy181,700$6.96$1,264,632.00View SEC Filing  
10/7/2014Jean GeorgeDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
10/7/2014Morgenthaler Venture PartnersMajor ShareholderBuy350,000$10.00$3,500,000.00View SEC Filing  
10/1/2014Adage Capital Partners Gp LlcMajor ShareholderBuy800,000$10.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Calithera Biosciences (NASDAQ:CALA)
Latest Headlines for Calithera Biosciences (NASDAQ:CALA)
Source:
Loading headlines, please wait.

Social

Chart

Calithera Biosciences (CALA) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.